Summary
56 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 100% a year over the last 3 years.
- Out of every 100 USD of revenue, 32 USD is left as net profit.
- It holds more cash than debt: $3.07B against $836.8M.
- The share price is below the Bulios Fair Price.
What to watch
- Operating profit covers the interest on its debt only 1.7 times.
- It earns only 0.0 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 0.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
Revenue grew by 314% a year over 5 years. Over the last 3 years it grew by 915% a year. Earnings per share grew by 100% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 56 USD
- Research and development 1,267 USD
- Sales and administration -1,224 USD
- Taxes and other -31 USD
- Net profit 32 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 32 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 28.5 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
- Product 95%
- Service 5.1%
By region
- UNITED STATES 60%
- Non-US 40%
Product brings in 95% of revenue.
Segments in detail